See more : Tsudakoma Corp. (6217.T) Income Statement Analysis – Financial Results
Complete financial analysis of Tryp Therapeutics Inc. (TRYPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tryp Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nhale, Inc. (NHLE) Income Statement Analysis – Financial Results
- Yuanta SPAC 16 (474490.KQ) Income Statement Analysis – Financial Results
- 3Peak Incorporated (688536.SS) Income Statement Analysis – Financial Results
- Kendrion N.V. (KENDR.AS) Income Statement Analysis – Financial Results
- Tokyo Finance Limited (TOKYOFIN.BO) Income Statement Analysis – Financial Results
Tryp Therapeutics Inc. (TRYPF)
About Tryp Therapeutics Inc.
Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.36M | 2.96M | 889.98K | 8.33K |
| General & Administrative | 2.37M | 4.40M | 4.41M | 386.62K |
| Selling & Marketing | 0.00 | 0.00 | 1.98M | 27.67K |
| SG&A | 2.37M | 4.40M | 6.40M | 414.29K |
| Other Expenses | -522.25K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.72M | 7.36M | 7.29M | 422.62K |
| Cost & Expenses | 4.72M | 7.36M | 7.29M | 422.62K |
| Interest Income | 1.75K | 3.25K | 10.93K | 0.00 |
| Interest Expense | 522.24K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K |
| EBITDA | -4.70M | -7.23M | -6.31M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.70M | -7.23M | -6.31M | -422.62K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -542.91K | -265.05K | -966.61K | 0.00 |
| Income Before Tax | -5.27M | -7.49M | -8.25M | -422.62K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 538.19K | 123.54K | 959.32K | -458.04 |
| Net Income | -5.27M | -7.49M | -8.25M | -422.62K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.05 | -0.10 | -0.12 | -0.01 |
| EPS Diluted | -0.05 | -0.10 | -0.12 | -0.01 |
| Weighted Avg Shares Out | 96.42M | 78.06M | 66.67M | 38.39M |
| Weighted Avg Shares Out (Dil) | 96.42M | 78.06M | 66.67M | 38.39M |
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million
Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
Tryp Therapeutics Announces Private Placement of Unsecured Convertible Debentures for Gross Proceeds of up to AUD$175,000
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
With Great Sadness Tryp Announces the Passing of David Tousley, Director
Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023
FDA Approves Psilocybin For Binge Eating Study By Tryp Therapeutics
Source: https://incomestatements.info
Category: Stock Reports